4BIO Capital
UK-headquartered biotech venture firm; led Cytospire £61m Series A in May 2026.
Last refreshed: 13 May 2026 · Appears in 1 active topic
How is 4BIO Capital shaping UK cell and gene therapy investment?
Timeline for 4BIO Capital
Cytospire's £61m oncology Series A oversubscribed
UK Startups and Innovation- What does 4BIO Capital invest in?
- 4BIO Capital invests in transformative biotherapies including cell therapies, gene therapies, and advanced biologics, typically leading Series A and B rounds in clinical-stage companies.Source: 4BIO Capital official
- Why did 4BIO Capital lead the Cytospire funding round?
- 4BIO Capital led Cytospire's oversubscribed £61m Series A in May 2026, backing the company's CAR-T pipeline for solid tumours, consistent with the firm's focus on advanced oncology therapies.Source: event
- Where is 4BIO Capital based?
- 4BIO Capital is headquartered in London, United Kingdom.Source: 4BIO Capital official
Background
4BIO Capital is a London-headquartered venture capital firm that specialises in transformative biotherapies — primarily cell therapies, gene therapies, and advanced biologics targeting serious diseases with few existing treatment options. The firm manages approximately $1bn in assets and takes an active investor role, providing portfolio companies with scientific, regulatory, and commercial expertise alongside capital. Its focus on clinical-stage companies means it typically leads or anchors Series A and B rounds where technical de-risking is the central investor task.
4BIO Capital led Cytospire's £61m oversubscribed Series A in May 2026, backing the London-based oncology company's chimeric antigen receptor T-cell (CAR-T) pipeline targeting solid tumours. The round was oversubscribed, indicating strong institutional appetite for UK clinical-stage oncology assets. 4BIO's lead position gives it preferential access to Cytospire's intellectual property and regulatory milestones, reinforcing the UK as a credible home for early-stage advanced-therapy investment.